The era of CD19-directed therapy in diffuse large B-cell lymphoma
- PMID: 33989556
- DOI: 10.1016/S1470-2045(21)00191-1
The era of CD19-directed therapy in diffuse large B-cell lymphoma
Conflict of interest statement
KM has consulted for Pharmacyclics, Janssen, Morphosys, Celgene, Beigene, Gilead, Karyopharm, ADC Therapeutics, and Seattle Genetics, outside of the submitted work.
Comment on
-
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989558 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources